Haywood Cochrane

Jan 09, 2017

Acuamark Diagnostics announced Haywood Cochrane has joined its board of directors. He will transition from his current position as a member of the firm's advisory board. Cochrane is currently a director at Corium and vice chair of the board at the University of North Carolina, Chapel Hill. Previously, he was CEO of CHD Meridian and was president and CEO of Allied Clinical Labs. 

More Like This

May 22, 2018

Erica Ramos

Erica Ramos, president of the National Society of Genetic Counselors, will join Geisinger National Precision Health at the end of May as the director and head of clinical and business development. Ramos was previously at Illumina, where she was associate director of market development in clinical genomics and lead the company's precision health and screening programs.

Geisinger National aims to extend the genomics research and actionable health information generated within its MyCode Community Health Initiative. Ramos will be in charge of strategic partnerships focused on implementing the MyCode model in other communities around the country. 

May 22, 2018

Nathan Wood

Nathan Wood has been appointed as CEO of Swift Biosciences, replacing Mark Lewis, who became CEO last year. Most recently, Wood was president of synthetic genomics company SGI-DNA. Previously, he held leadership positions at several genomics and life sciences companies, including Life Technologies and Qiagen.

May 18, 2018

William Denman

William Denman, chief medical officer and founding member of Premaitha Health, has stepped down as director and consultant to the company.

May 15, 2018

Jeffrey Bluestone, Vijay Kuchroo, Christoph Lengauer, Aviv Regev, Ramnik Xavier, Alexis Borisy, Jeff Ross, Anthony Philippakis, Maya Said, Jason Coloma, Susan O'Connor

Celsius Therapeutics has named its founders and leadership team.

The company's founders are Jeffrey Bluestone, president and CEO of the Parker Institute for Cancer Immunotherapy at the University of California, San Francisco; Vijay Kuchroo, professor of neurology at Harvard Medical School; Christoph Lengauer, venture partner at Third Rock Ventures; Aviv Regev, chair of the faculty, core member, and director of the Klarman Cell Observatory at the Broad Institute; and Ramnik Xavier, chief of gastroenterology at Massachusetts General Hospital. Lengauer is also Celsius' president.

Alexis Borisy, a partner at Third Rock Ventures, serves as executive chairman of the company's board of directors, and Lengauer is a board member. Regev is a board observer, along with Jeff Ross, cofounder of Syfr, and Anthony Philippakis, a venture partner at GV (formerly Google Ventures).

The firm's management team includes Maya Said, chief operating officer; Jason Coloma, chief business officer; and Susan O'Connor, chief people officer.

May 15, 2018

Rolland Carlson, Tanja Dowe, Katleen Verleysen

Immunexpress has appointed Rolland Carlson, Tanja Dowe, and Katleen Verleysen to its board. The company also noted that Bea Arnold has stepped down from the board after a three-year tenure.

Carlson was appointed CEO of Immunexpress last month, and previously served as president and CEO at both WaferGen Biosystems and Asuragen. Dowe currently serves as CEO of Debiopharm Innovation Fund, the strategic corporate fund of Debiopharm Group. Verleysen is CEO of CellSeeQ. Prior to that, she held various positions at Pronota, including CEO and chief operating officer.

May 15, 2018

Vasudev Rangadass

L7 Informatics (formerly Lab7 Systems) has named Vasudev Rangadass as its CEO. Rangadass joined the company from NantHealth, where he served as chief strategy officer following NantHealth's acquisition of Net.Orange, a company Rangadass founded to provide enterprise solutions to the healthcare industry. Prior to Net.Orange he was the first employee of i2 Technologies.

May 14, 2018

Greg Shaw

Angle announced today that it has appointed Greg Shaw to its scientific advisory board. Shaw is currently a consultant urological surgeon at the University College Hospital in London. He is also chief investigator for two studies at the National Institute for Health Research investigating the effects of refinements to robotic surgery and the use of drugs to prevent progression in men on active surveillance for prostate cancer. 

May 08, 2018

Stephanie Bywater

Stephanie Bywater has been appointed chief compliance officer at NeoGenomics. Her appointment became effective May 1, and she replaces Steven Jones, who will remain an executive vice president and board member at the company. Jones and NeoGenomics reached an agreement in November 2016 where he would reduce his time commitment to the firm, effective May 1 2018.

Bywater has been compliance officer at NeoGenomics since May 2017 when she joined the firm. She was previously global compliance operations and Americas compliance officer at Varian Medical Systems. Before that, she was the compliance and prvacy officer for Myriad Genetics. 

May 08, 2018

Michael Stocum

Michael Stocum has stepped down as CEO of Inivata "to pursue other interests," according to the company. Inivata said it has initiated a search for a new CEO.

May 08, 2018

Terry Pizzie

Horizon Discovery Group has appointed Terry Pizzie as CEO and board member, effective immediately. Pizzie joined Horizon in 2017 as head of commercial operations and has nearly 30 years of experience in the biotechnology tools sector. Prior to joining Horizon, Pizzie worked for Pacific Biosciences, first as a vice president in Europe, and later as head of global sales. His previous leadership roles include director of global commercial operations at Genetix prior to its acquisition by Danaher, and senior vice president of global commercial operations at Swedish biotech firm Biacore. He started his career at Applied Biosystems in 1988.

May 04, 2018

Berndt Modig

Centogene announced today that it has appointed Berndt Modig to its supervisory board. Modig currently serves as director and audit committe chair of Axovant Sciences, member of the audit committee of Affimend, and vice chairman of the supervisory board and chair of the audit committee at Kiadis Pharma. In addition, Modig is currently CEO and co-founder of Pharvaris.

Modig previously served as CFO of Prosensa Hodling from Mar. 2010 until its 2015 acquisiotn by BioMarin Pharmaceutical. Prior to Prosensa holding, Modig was CFO at Jerini AG. Modig has also held a variety of senior management positions at Surplex AG, Hayward Industrial Products, Agra Industrial, and Price Waterhouse. 

May 04, 2018

Charles Bodner

Becton Dickinson has elected Charles Bodner to the role of senior vice president of corporate finance and chief accounting officer. Effective July 1, 2018, Bodner will replace John Gallagher, who will transition to another senior role at BD. Bodner has been BD's senior vice president and CFO of the firm's medical segment since 2013, and CFO of the international business segment since 2017.

May 04, 2018

Alberto Mas, Patrick Kaltenbach, Bill Tozzi

Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.

Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Mas was head of Life Sciences for two years, and previously served as president of three of the firms other major business units. 

Kaltenbach will replace Mas effective May 29, 2018. He previously served as senior vice president of life sciences and applied markets at Agilent, a position he held since 2014.

Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

May 01, 2018

John Roberts

Cancer Genetics has appointed John Roberts as CEO and president. Roberts had been serving as interim CEO since February, in addition to serving as chief operating officer and executive VP of finance, positions he has held since July 2016. Roberts served as CFO for VirMedica from August 2015 to June 2016. Prior to VirMedica, Roberts served as chief financial and administrative officer for AdvantEdge Healthcare Solutions, CFO and treasurer for InfoLogix, and as CFO at public medical device and healthcare firms including Clarient and Daou Systems.

Apr 30, 2018

Maneesh Arora

Exact Sciences Chief Operating Officer Maneesh Arora will be leaving the company at the end of the year. During a conference call with analysts following the release of the company's first quarter earnings, Exact CEO Kevin Conroy announced that Arora "will transition to a life outside of Exact Sciences," adding that he will spend the rest of 2018 "focusing his operational and strategic rigor on the priority of advancing our pipeline plans to fuel our future success." The company does not anticipate finding a replacement COO at this time, Conroy noted.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.